These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26253624)

  • 1. Kynurenine pathway (KP) inhibitors: Novel agents for the management of depression.
    Hazari N; Bhad R
    J Psychopharmacol; 2015 Oct; 29(10):1133-4. PubMed ID: 26253624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation in cancer and depression: a starring role for the kynurenine pathway.
    Sforzini L; Nettis MA; Mondelli V; Pariante CM
    Psychopharmacology (Berl); 2019 Oct; 236(10):2997-3011. PubMed ID: 30806743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathobiological targets of depression.
    Chopra K; Kumar B; Kuhad A
    Expert Opin Ther Targets; 2011 Apr; 15(4):379-400. PubMed ID: 21254923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection.
    Stone TW; Forrest CM; Darlington LG
    FEBS J; 2012 Apr; 279(8):1386-97. PubMed ID: 22248239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats.
    Fischer CW; Eskelund A; Budac DP; Tillmann S; Liebenberg N; Elfving B; Wegener G
    Behav Brain Res; 2015 Oct; 293():166-72. PubMed ID: 26205824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway.
    Fabbri C; Marsano A; Albani D; Chierchia A; Calati R; Drago A; Crisafulli C; Calabrò M; Kasper S; Lanzenberger R; Zohar J; Juven-Wetzler A; Souery D; Montgomery S; Mendlewicz J; Serretti A
    Pharmacogenomics J; 2014 Oct; 14(5):463-72. PubMed ID: 24709691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy.
    Pertl MM; Hevey D; Boyle NT; Hughes MM; Collier S; O'Dwyer AM; Harkin A; Kennedy MJ; Connor TJ
    Brain Behav Immun; 2013 Nov; 34():108-19. PubMed ID: 23928287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].
    Chaki S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biogenic amines and depression. The potential value of biochemical parameters in the diagnosis and medication of affective disorders.
    Ridges AP
    Postgrad Med J; 1976; 52(3 suppl):9-17. PubMed ID: 785425
    [No Abstract]   [Full Text] [Related]  

  • 10. The roles of neurotrophic factor and Wnt signaling in depression.
    Voleti B; Duman RS
    Clin Pharmacol Ther; 2012 Feb; 91(2):333-8. PubMed ID: 22205198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin Pathway: A Potential Target for the Treatment of Depression.
    Ma C; Cheng F; Wang X; Zhai C; Yue W; Lian Y; Wang Q
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27164096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling.
    Mackay GM; Forrest CM; Christofides J; Bridel MA; Mitchell S; Cowlard R; Stone TW; Darlington LG
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):425-35. PubMed ID: 19018805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and molecular mechanisms underlying the treatment of depression: focusing on hippocampal G-protein-coupled receptors and voltage-dependent calcium channels.
    Pavlovicova M; Lacinova L; Dremencov E
    Gen Physiol Biophys; 2015 Oct; 34(4):353-66. PubMed ID: 25926550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
    Dounay AB; Tuttle JB; Verhoest PR
    J Med Chem; 2015 Nov; 58(22):8762-82. PubMed ID: 26207924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kynurenine pathway in brain tumor pathogenesis.
    Adams S; Braidy N; Bessede A; Brew BJ; Grant R; Teo C; Guillemin GJ
    Cancer Res; 2012 Nov; 72(22):5649-57. PubMed ID: 23144293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway.
    Forrest CM; Khalil OS; Pisar M; McNair K; Kornisiuk E; Snitcofsky M; Gonzalez N; Jerusalinsky D; Darlington LG; Stone TW
    Neuroscience; 2013 Dec; 254():241-59. PubMed ID: 24076085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tramadol in the rat forced swimming test.
    Jesse CR; Bortolatto CF; Savegnago L; Rocha JB; Nogueira CW
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1838-43. PubMed ID: 18773934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant-like effect of atorvastatin in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway.
    Shahsavarian A; Javadi S; Jahanabadi S; Khoshnoodi M; Shamsaee J; Shafaroodi H; Mehr SE; Dehpour A
    Eur J Pharmacol; 2014 Dec; 745():52-8. PubMed ID: 25446923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational use of psychotropic drugs. IV. Antidepressants.
    Greenblatt DJ; Shader RI
    Am J Hosp Pharm; 1975 Jan; 32(1):59-64. PubMed ID: 1168415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sigma receptors: potential targets for a new class of antidepressant drug.
    Fishback JA; Robson MJ; Xu YT; Matsumoto RR
    Pharmacol Ther; 2010 Sep; 127(3):271-82. PubMed ID: 20438757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.